investigated whether adding the aldosterone receptor antagonist spironolactone to renin–angiotensin system inhibition improved proteinuria in patients with diabetic nephropathy. Patients with ...

The landmark Randomized Aldactone Evaluation Study (RALES), published in 1999, showed that spironolactone, a potassium-sparing diuretic, improves outcomes in patients with severe heart failure.

spironolactone, and digoxin in combination with sodium and fluid restriction. Strategies to combat diuretic resistance include sequential nephron blockade with combination loop and thiazide or ...

The routine administration of spironolactone to patients after a myocardial infarction (MI) did not reduce either of the coprimary outcomes in the CLEAR SYNERGY (OASIS 9) trial. However ...

Among 203 patients, 71% of those taking SZC achieved the primary endpoint of optimal response -- normokalemia while on at least a 25-mg dose of spironolactone daily without rescue therapy for ...